All In Biotech

Drug Trial Radar · NCT01698684

Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction

A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Oct 27, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 440 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

440

Actual

Start

Sep 2012

Primary completion

Apr 2013

Study completion Apr 2013

Sponsor

Lead sponsor
VIVUS LLCIndustry
Sponsor type
Industry
First posted
Oct 3, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to examine the therapeutic effects of two doses of avanafil after dosing in men with erectile dysfunction

Conditions

  • Erectile Dysfunction

Interventions

  • PlaceboDrug

    One dose 15 minutes before attempting intercourse

  • Avanafil 100 mgDrug

    One dose 15 minutes before attempting intercourse

  • Avanafil 200 mgDrug

    One dose 15 minutes before attempting intercourse

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Per-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following DosingTime frame: Week 0 (Baseline) up to Week 8 (End of Study)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Jupiter, Florida

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Wilmington, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.